

# MSS 2024

HYBRID

## Manufacturing of mRNA for preclinical and clinical studies

*Tjaša Legen, Maximilian Buff, Lena Wicke, Andreas Kuhn*

*BioNTech SE, Mainz, Germany*

Advances in messenger RNA (mRNA)-based therapeutics have ignited optimism in the fight against a broad spectrum of illnesses and infectious diseases. mRNA therapeutics are often produced via a simple and highly adaptable in vitro transcription process, which can accelerate the development of novel drugs and their subsequent transfer to the commercial market. However, scaling up mRNA production and purification, while minimizing impurities and by products, remains challenging. Thus, manufacturing of mRNA for preclinical and clinical studies requires well designed and robust processes with well characterized analytical strategies. Our aim is to develop a highly adaptable and simplified process for a broad range of therapeutics and drugs manufactured for even the smallest groups of patients. This presentation will discuss process development and transfer of mRNA production to the manufacturing scale.

 PORTOROZ, SLOVENIA

 3-7 June 2024